Telaglenastat/cabozantinib combination shows early activity in metastatic kidney cancer

Telaglenastat is an oral glutaminase inhibitor and this is the first time it has been administered to humans. Glutaminase is a key enzyme that controls the glutamine pathway that is prominent in renal cell carcinoma (RCC) and important for the tumour to thrive in the body. In pre-clinical models, telaglenastat was found to synergise with […]

read more

Real-world outcomes of nivolumab and cabozantinib for metastatic kidney cancer

A retrospective study using data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) dataset looked at the efficacy of nivolumab (225 patients) and cabozantinib (53 patients) when used to treat metastatic renal cell carcinoma (RCC) in the real world. The study found similar outcomes for patients treated with nivolumab and cabozantinib in the […]

read more

Complete response of kidney cancer brain metastases to cabozantinib

A recent case study, reported in Case Reports in Urology, presented an unusual case of a patient with metastatic renal cell carcinoma (RCC) and brain metastases who experienced a complete response to cabozantinib prior to radiation therapy. This case study contributes to the limited evidence on the activity of cabozantinib within the brain. The researchers […]

read more

Patients may not be able to tolerate recommended dose of cabozantinib

A recent study published on Oncology this month suggests that renal cell carcinoma (RCC) patients may not be able to tolerate the FDA-approved dose of cabozantinib, which was determined from the METEOR and CABOSUN clinical trials. In the current trial, a median daily dose of 33.2 mg was less than that administered in the METEOR […]

read more

Cabozantinib in advanced non-clear cell kidney cancer

A recent study, published in The Lancet Oncology, has provided evidence of the effectiveness of cabozantinib for patients with non-clear cell renal cell carcinoma (RCC). This real world study identified 112 patients with non-clear cell RCC treated with cabozantinib at hospitals in the USA and Belgium. Most had papillary histology (66 patients, 59%), 17 (15%) […]

read more

ASCO GU 2019: Early tumour shrinkage and improved survival with cabozantinib

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Ignacio Durán, of the Hospital Universitario Marqués de Valdecilla in Spain, presented new results from the phase 3 METEOR trial showing that patients with advanced renal cell carcinoma (RCC) treated with cabozantinib […]

read more

First-line cabozantinib declined for a second time for use within NHS Scotland

Cabozantinib has been declined for a second time by the Scottish Medicines Consortium (SMC) for use within NHS Scotland for people with untreated, intermediate-risk or poor-risk advanced renal cell carcinoma (RCC). KCSN are extremely disappointed with this decision, which was made despite new anecdotal evidence as to the effectiveness of the drug against advanced RCC submitted in response to […]

read more

ESOU 2019: First-line treatment for metastatic renal cell carcinoma – where do we stand?

The following review of the literature for first-line treatment of metastatic renal cell carcinoma (RCC) was presented at the European Association of Urology (EAU) Section of Oncological Urology (ESOU) conference in Prague, Czech Republic last week. The current paradigm for the first- and second-line treatment of RCC was presented based upon patient risk according to the International Metastatic Renal […]

read more

Cabozantinib for the treatment of non-clear cell kidney cancer

A recent study published in the European Journal of Cancer shows that cabozantinib produced a clinically meaningful benefit in people with metastatic non-clear cell renal cell carcinoma (RCC), most of whom had disease progression on prior vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). In this retrospective study, 30 patients with metastatic non-clear cell […]

read more

ESMO 2018: Cabozantinib in combination with atezolizumab in metastatic kidney cancer

The following video interview from Practice Update discusses the promising results from the phase 1b trial of cabozantinib in combination with atezolizumab for metastatic renal cell carcinoma (RCC), the results of which were presented at the European Society of Medical Oncology (ESMO) conference in Munich, Germany last week. Watch the video interview from Practice Update here

read more
Showing 11 to 20 of 66 results
  TOP